Presentation is loading. Please wait.

Presentation is loading. Please wait.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Published byMelvin Reynolds Modified over 4 years ago

Similar presentations

Presentation on theme: "Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo."— Presentation transcript:

1 Parthenolide inhibits tumor promotion and increases p21 expression in vivo.
Parthenolide inhibits tumor promotion and increases p21 expression in vivo. PTL was administered intraperitoneally on day 0, at a dose of 0.25 mg/kg into NMRI-Nu immunocompromised adult male mice. The drug was given every other day over a 10-day period, as indicated with arrows. JB6P+ cells were promoted with TPA and serum for 6 days in culture and injected, on day 10, subcutaneously into the shoulder region of PTL- or control (Ct)-treated mice. After tumor cell injection, PTL treatment was either ceased (A) or continued, as indicated with arrows, till the first appearance of the tumors, which was approximately after 10 additional days (B). Values represent the average ± SEM of (A) 1 experiment with 15 mice per group and of (B) 3 experiments with a total of 13 mice per group. Statistical significance between Ct and PTL is shown at specific days (*, P < 0.05; ***, P < 0.001) and for the overall duration of the experiments by brackets P < using 2-way ANOVA. C, TMA scores for Ki67, p21, and p65 from tumors taken from the mice in experiment (A). Scores represent the average ± SEM of the mean percentage staining of triplicate punches for each of 15 mouse tumors; statistical comparisons were done using independent sample t test. *, P < 0.05; **, P < 0.01; ***, P < Akram Ghantous et al. Cancer Prev Res 2012;5: ©2012 by American Association for Cancer Research

Download ppt "Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo."

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Volume 8, Issue 6, Pages (December 2005)

Volume 8, Issue 6, Pages (December 2005)
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Fig. 5 Local gel scaffold for T cell memory response.

Fig. 5 Local gel scaffold for T cell memory response.
Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.
Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Similar presentations

Ads by Google